

**AMENDMENTS TO THE CLAIMS**

**1. (Currently amended)** A sustained-release preparation comprising (1) a dipeptidyl peptidase IV inhibitor and (2) a hydrophilic polymer selected from hydroxypropyl cellulose and hydroxypropylmethyl cellulose, wherein the content of the hydrophilic polymer in the preparation is 5-90 wt%.

**2. (Currently amended)** The sustained-release preparation of claim 1, wherein the content of the hydroxypropyl cellulose or hydroxypropylmethyl cellulose in the preparation is 10-80 wt%~~hydrophilic polymer in the preparation is not less than 5 wt%.~~

**3. (Original)** The sustained-release preparation of claim 1, which is used for the prophylaxis or treatment of diabetes.

**4. (Original)** The sustained-release preparation of claim 1, which is a hypoglycemic agent.

**5-20. (Cancelled)**

**21. (New)** The sustained-release preparation of claim 1, which is capable of decreasing dipeptidyl peptidase IV activity in plasma by 10 to 90% at 1 hr after administration.

**22. (New)** The sustained-release preparation of claim 1, which is capable of decreasing dipeptidyl peptidase IV activity in plasma by 10 to 90% at 8 hr after administration.

**23. (New)** The sustained-release preparation of claim 1, which is capable of decreasing dipeptidyl peptidase IV activity in plasma by 10 to 90% over the period of 1 hr to 8 hr after administration.